onc Videos

Videos

Andrew Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

Videos

Zanubrutinib Plus Obinutuzumab and Venetoclax With MRD-Driven Discontinuation Shows Promise in CLL/SLL

05/14/2022

Andrew Zelenetz, MD, PhD, discusses results from a phase 2 trial assessing triplet therapy with zanubrutinib, obinutuzumab, and venetoclax in previously untreated CLL or SLL and exploring MRD as a biomarker for treatment duration.

Andrew Zelenetz, MD, PhD,...

05/14/2022

Oncology

Videos

3D Cultivation Improves Survival Time of Primary Mantle Cell Lymphoma Cells, Enables Long-term Experiments

04/30/2022

Kathrin Böpple, PhD, and Meng Dong, PhD discuss the development of a 3D cultivation system with alginate hydrogel that improves the in vitro survival time of primary mantle cell lymphoma cells.

Kathrin Böpple, PhD, and Meng...

04/30/2022

Oncology

Videos

Successful Manufacturing of Lisocabtagene Maraleucel for Patients With CLL

04/18/2022

Tanya Siddiqi, MD, shares results and insights of the TRANSCEND CLL 004 study of lisocabtagene maraleucel, a CD19-directed CAR T-cell therapy for patients with CLL.

Tanya Siddiqi, MD, shares...

04/18/2022

Oncology

Videos

Study Profiles T-Cell Subpopulations Based on Spatial Proteome in MCL

04/18/2022

Lavanya Lokhande, PhD, discusses results from a study, presented at the AACR Annual Meeting, which investigated T-cell subpopulations profiled by spatial proteome among patients with MCL.

Lavanya Lokhande, PhD, discusses...

04/18/2022

Oncology

Videos

Loss of GTPase RhoA Impairs Lenalidomide Activity in MCL

04/18/2022

Gaël Roué, PhD, highlights a study providing insight into how the loss of the small GTPase RhoA enhances lymphomagenesis and impairs the activity of lenalidomide in patients with MCL.

Gaël Roué, PhD, highlights a...

04/18/2022

Oncology

Videos

Impact of CD163-Positive Cells on MCL Development and Treatment Response

04/13/2022

A study presented at the AACR Annual Meeting demonstrates that spatial localization within the MCL tumor affects the expression of CD163-positive macrophages and identifies possible targetable markers.

A study presented at the AACR...

04/13/2022

Oncology

Vivek Subbiah, MD, MD Anderson Cancer Center

Videos

Next Steps for Pemigatinib on FGFR Inhibition With Multiple Tumors, FDA Approval

04/11/2022

Vivek Subbiah, MD, University of Texas, shares updates of pemigatinib in the upcoming FIGHT-302 study and highlights how an FDA approval will benefit patients with CCA harboring an FGFR2 mutation.

Vivek Subbiah, MD, University of...

04/11/2022

Oncology

Susan Fineberg, MD, Montefiore Medical Center

Videos

EZH2 Biomarker Predicts Metastatic Disease in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy

04/08/2022

Susan Fineberg, MD, overviews EZH2 expression in the neoadjuvant setting to predict metastatic recurrence for patients with TNBC.

Susan Fineberg, MD, overviews...

04/08/2022

Oncology

Videos

Long-term Safety of Rituximab Biosimilar in Untreated Advanced FL

04/07/2022

Christian Buske, MD, overviews a phase 3 study on the long-term safety and efficacy of CT-P10, a rituximab biosimilar, in patients with untreated advanced FL.

Christian Buske, MD, overviews a...

04/07/2022

Oncology

Videos

Pemigatinib Safe, Demonstrates Encouraging Responses Among Patients With Advanced Malignancies and an FGFR Mutation: FIGHT-101 Trial

04/01/2022

Vivek Subbiah, MD, University of Texas, overviews the FIGHT-101 trial on pemigatinib, a selective FGFR 1-3 inhibitor, which targets mutations across a variety of tumor types.

Vivek Subbiah, MD, University of...

04/01/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology